Acute Coronary Syndromes

Acute coronary syndrome (ACS) is most commonly caused by a heart attack (myocardial infarction) where blood flow to the heart is suddenly blocked. This is usually caused by a blood clot from a ruptured coronary artery atherosclerotic plaque. Other causes include spontaneous coronary artery dissection (SCAD), which most commonly occurs in women. ACS is usually treated in a cath lab with angioplasty and the placement of a stent to prop the vessel open.

RSS icon
Product Recall

FDA announces Class I recall of nearly 8,000 heart attack tests due to inaccurate results

Overall, the recall includes 7,799 blood tests intended to help physicians identify early signs of a myocardial infarction. 

July 17, 2023
IVUS guidance during DES implantation boosts long-term outcomes in new study

Heart failure symptoms after PCI increase risk of adverse events

Researchers in Japan tracked BNP levels and bleeding events among more than 7,000 PCI patients. The group noted that managing heart failure in the first 30 days after PCI can help boost outcomes. 

July 7, 2023
AI artificial intelligence stethoscope doctor

AI model outperforms researchers’ ‘wildest dreams’ with accurate heart attack assessments

The algorithm, developed using data from more than 7,00 chest pain patients, performed better than multiple techniques currently used to evaluate cardiac events. 

June 30, 2023
Colchicine Lodoco Agepha Pharma price cost cardiovascular disease CVD

What will Lodoco cost? Looking ahead after FDA’s historic approval of colchicine for CVD

“Our pricing strategy for Lodoco is focused on helping to ensure access to as many people as possible,” an executive with Agepha Pharma told Cardiovascular Business. 

June 27, 2023
The U.S. Food and Drug Administration (FDA) priority review, the FDA has cleared the Agepha Pharma USA LLC's drug Lodoco (colchicine) as the first anti-inflammatory atheroprotective cardiovascular treatment. Colchicine prevents coronary artery plaque inflammation, heart inflammation. Colchicine for coronary artery disease. Colchicine for coronary inflammation FDA Approves Colchicine for Decreasing CV Events FDA Approves Colchicine for decreasing inflammation caused by coronary atherosclerosis.

Cardiologists applaud FDA’s approval of colchicine for CVD

"The FDA's approval of colchicine confirms that we are entering a new era of patient care," said one veteran cardiologist familiar with the drug. 

June 26, 2023
The U.S. Food and Drug Administration (FDA) priority review, the FDA has cleared the Agepha Pharma USA LLC's drug Lodoco (colchicine) as the first anti-inflammatory atheroprotective cardiovascular treatment. Colchicine prevents coronary artery plaque inflammation, heart inflammation. Colchicine for coronary artery disease. Colchicine for coronary inflammation FDA Approves Colchicine for Decreasing CV Events FDA Approves Colchicine for decreasing inflammation caused by coronary atherosclerosis.

FDA approves colchicine, the first anti-inflammatory drug for treating cardiovascular disease

The FDA's approval of colchicine, which is marketed and sold under the name Lodoco, is expected to have a big impact on cardiac care and outcomes.

June 20, 2023
Money dollar investments

Bitterroot Bio, a new biotech company launched by physicians and industry veterans, raises $145M

The new company formed in 2021, but waited until now to publicly launch. Its founders included two Stanford University physicians.

June 8, 2023
Recall | Product recall

FDA announces recall of certain Impella heart pumps after 3 patient injuries, nearly 200 complaints

The FDA has labeled this as a Class I recall, which means using these devices can lead to significant injuries, including death.

June 5, 2023
Displaying 81 - 88 of 613

Around the web

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Design by Adaptive Theme
Trimed Popup
Trimed Popup